<DOC>
	<DOCNO>NCT02758925</DOCNO>
	<brief_summary>Forty percent patient diffuse large B cell lymphoma ( DLBCL ) primary refractory relapse disease ( R/R ) . For fit patient , standard treatment second line therapy high dose therapy autologous stem cell transplantation ( ASCT ) . In 48 % DLBCL ASCT possible due progressive disease . For patient ineligible transplantation patient , salvage therapy often rituximab-gemcitabine-oxaliplatine regimen overall response rate ( ORR ) 50 % . Bendamustine combination rituximab , use single agent set R/R DLBCL patient , show ORR 62.7 % 45.8 % good safety profile . Bendamustine cytarabine ( BAC ) show high synergy induce cell death mantle cell lymphoma DLBCL cell line . In recent phase II study , combination cytarabine Rituximab Bendamustine ( R-BAC ) patient mantle cell lymphoma previously untreated , refractory relapse evaluate . The efficacy safety R-BAC association evaluate phase II trial enrol 78 patient relapsed refractory DLBCL .</brief_summary>
	<brief_title>CyBeR Association Relapsed/Refractory DLBCL</brief_title>
	<detailed_description>Participants receive 6 cycle every 21 day follow-up period 24 month . CT-Scan 3 cycle end treatment use assess treatment response , establish Cheson criterion 1999 . Principal objective obtain overall response rate 60 % ( correspond increase 15 % rituximab-gemcitabine-oxaliplatine regimen 's overall response rate ) . Secondaries objectives value toxicity , progression free survival overall survival .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>1. patient 18 75 year 2 . Patient sharpen social security system 3 . Patients relapse refractory diffuse large B cell lymphoma receive least one prior line immunochemotherapy unfit intensive regimen therapy autologous stem cell transplantation ( ASCT ) eligible patient stem cell transplantation failure salvage therapy patient relapse ASCT 4 . Not previously treat bendamustine 5. WHO performance status 0 , 1 2 6 . Adequate hematological function define : leucocyte count ≥ 3.0 109/L , platelet count ≥ 75 109/L 7 . Females childbearing potential must agree medically acceptable method contraception study treatment initiation end treatment . 8 . Signed informed consent . 1 . Person guardianship curatorship , unable understand purpose study 2 . Central nervous system meningeal involvement 3. WHO performance status 2 4 . Contraindication drug contain chemotherapy regimen 5 . HIV disease , active hepatitis B C 6 . Any serious active disease comorbid medical condition 7 . Any following laboratory abnormality . Leucocyte count &lt; 3.0 x 109/L Platelet count &lt; 75 x 109/L 8 . Any serious medical condition , laboratory abnormality , psychiatric illness would prevent subject signing informed consent form . 9 . Pregnant lactating female . 10 . Prior history malignancy , lymphoma , unless patient free disease ≥ 3 year . Exceptions include follow : Basal cell carcinoma skin . Squamous cell carcinoma skin . Carcinoma situ cervix . Carcinoma situ breast . Incidental histological finding prostate cancer ( TNM stage T1a T1b ) . 11. renal impairment estimate ( modify dietin renal disease ; MDRD ) creatinine clearance &lt; 40 ml/min , 12. chronic liver disease day1 ( AST/ALT ) ≥2.5 upper limit normal ( ULN ) , total bilirubin≥1.5 ULN ,</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>